Chemistry:6-MAPB

From HandWiki

6-MAPB (1-(benzofuran-6-yl)-N-methylpropan-2-amine) is an entactogen of the benzofuran family which is structurally related to 6-APB and MDMA.[1][2][3][4][5] It is known to be a serotonin releasing agent and, unlike MDMA, a potent serotonin 5-HT1B receptor agonist.[6] The drug is not known to have been widely sold as a "designer drug" but has been detected in analytical samples taken from individuals hospitalised after using drug combinations that included other benzofuran derivatives. 6-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014.[7][8] It was banned in the United Kingdom in June 2013, along with 9 other related compounds which were thought to produce similar effects.[9]

Interactions

See also

References

  1. "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". J Psychopharmacol 35 (5): 512–536. May 2021. doi:10.1177/0269881120920420. PMID 32909493. 
  2. "Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MS(n) techniques". Analytical and Bioanalytical Chemistry 407 (12): 3457–3470. May 2015. doi:10.1007/s00216-015-8552-2. PMID 25711990. https://researchonline.ljmu.ac.uk/id/eprint/3412/1/ABC-02336-2014.R1.pdf. 
  3. "New Psychoactive Substances: Chemistry, Pharmacology, Metabolism, and Detectability of Amphetamine Derivatives With Modified Ring Systems". Therapeutic Drug Monitoring 38 (1): 4–11. February 2016. doi:10.1097/FTD.0000000000000240. PMID 26327309. 
  4. "Neurochemical binding profiles of novel indole and benzofuran MDMA analogues". Naunyn-Schmiedeberg's Archives of Pharmacology 390 (1): 15–24. January 2017. doi:10.1007/s00210-016-1297-4. PMID 27650729. 
  5. "The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats". Psychopharmacology 237 (12): 3703–3714. December 2020. doi:10.1007/s00213-020-05648-z. PMID 32875347. 
  6. Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", US patent 20230150963, published 2023 May 18, assigned to Tactogen
  7. "New phenethylamines in Europe". Drug Test Anal 6 (7-8): 808–818. 2014. doi:10.1002/dta.1570. PMID 24574327. 
  8. https://isomerdesign.com/bitnest/external/EMCDDA/New-Drugs-In-Europe-2013
  9. "Temporary class drug order report on 5-6APB and NBOMe compounds". UK Home Office. 4 Jun 2013. https://www.gov.uk/government/publications/temporary-class-drug-order-report-on-benzofury-and-nbome-compounds.